2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T707, Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease, significantly impacting a patient's quality of life. To date, a substantial proportion of patients present an insufficient response to available treatment options. Lebrikizumab, a monoclonal antibody targeting interleukin 13, has shown a promising clinical benefit in phase 3 trials, however, real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited and mostly restricted to Asian populations. Aim of this study was to evaluate the real-world effectiveness and safety of lebrikizumab in patients with AD. This retrospective study included 35 patients from a largely homogenous Central European population with moderate to severe Atopic Dermatitis treated with lebrikizumab at the Dermatology Department of the St. Josef-Hospital in Bochum between December 2023 and April 2025. Eczema area and severity index (EASI), SCORing Atopic Dermatitis (SCORAD), peak-pruritus (PP)-numerical rating scale (NRS) and dermatology life quality index (DLQI) were assessed during the treatment. Lebrikizumab reduced all clinical indices by week 4, with improvements maintained through week 16. At week 24, the achievement rates for EASI-50 (50% reduction in EASI), EASI-75 (75% reduction in EASI) and EASI-90 (90% reduction in EASI) were 100%, 75% and 75%, respectively, and the SCORAD-50 (50% reduction in SCORAD) response rate was 64.2%. The proportions of patients achieving a ≥ 4-point reduction in the PP-NRS and in the DLQI at week 24 were 55.8% and 91.6%, respectively. No new safety signals were observed. Lebrikizumab demonstrated favorable real-world effectiveness and safety over 24 weeks in patients with moderate-to-severe AD, supporting its use in routine clinical practice.31:T4f6,Tralokinumab, an anti-IL-13 antibody, is effective for atopic dermatitis (AD); however, its long-term (> 1 year) effectiveness specific to each anatomical site is unknown in real-world settings. To evaluate 72-week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate-to-severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.32:T54c,ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.33:Teb5,Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials. However, real-world data remain limited, largely restricted to Asian populations. This 16-week retrospective multicenter study included 78 adults from a predominantly white cohort with moderate-to-severe AD treated with lebrikizumab throughout 2024. Patients were both naïve and experienced with biologics or Janus kinase inhibitors (bio/JAKi-naïve or -experienced). The primary outcome for disease severity and therapeutic response was measured using the Eczema Area and Severity Index (EASI). Secondary outcomes included the Dermatology Life Quality Index (DLQI), itch- and sleep-numerical rating scales (NRS), body surface area (BSA), Investigator Global Assessment (IGA), SCORing Atopic Dermatitis (SCORAD), and Patient-Oriented Eczema Measure (POEM). Atopic Dermatitis Control Tool (ADCT) and minimal disease activity (MDA) were used to estimate disease control, and Hospital Anxiety and Depression Scales to monitor mental health status. At week 16, benefits in disease severity were observed for EASI (- 15.8 ± 9.4, p < 0.0001) and EASI head and neck (- 2.0 ± 1.7, p < 0.0001). QoL significantly improved in 70% of patients (DLQI reduction of - 12.6 ± 9.3, p < 0.0001), accompanied by decreased pruritus (Itch-NRS reduction of - 4.6 ± 3.2, p < 0.0001) and better sleep quality (sleep-NRS reduction of - 4.1 ± 3.4, p < 0.0001). A 76% reduction in BSA score was recorded, 85% of subjects improved their IGA index, with 62% achieving a score of 0-1, and SCORAD and POEM assessments significantly improved (p < 0.0001). Patients perceived a better control of the disease (ADCT, - 10.9 ± 7.1, p < 0.0001), and 14% of patients achieved MDA. Anxiety and depression levels decreased. Four mild adverse events were registered. This is one of the first real-world multicenter studies in a predominantly adult white population showing that lebrikizumab is effective, safe and improves symptoms, QoL, and mental health in moderate-to-severe AD bio/JAKi-naïve and -experienced patients. Atopic dermatitis is a chronic inflammatory skin condition that can impact quality of life. Lebrikizumab, a new biological drug, proved to be effective and safe. This is one of the first studies investigating the benefit of lebrikizumab use in routine clinical practice in predominantly white adults. The study included 78 adults who were treated with lebrikizumab for 16 weeks between January and December 2024. Some patients had never used biologic treatments before, while others had been treated using different therapies. Different evaluations of the benefit of treatment were performed by physicians and patients, assessing the severity of the disease, including skin appearance, itchiness, and how much of the body was affected. The impact on the quality of life and mental health, including itch levels, sleep quality, anxiety and depression states, and overall control over the disease was also evaluated. After 16 weeks, most patients reported major improvements. The severity of their skin symptoms and itch reduced significantly, and 76% had less body surface area affected. About 70% of patients reported an improvement in their quality of life. Itch and sleep improved, anxiety and depression levels decreased, and patients felt more in control of their condition. Only three mild side effects and one relapse were reported. Overall, this study shows that lebrikizumab is safe and effective for the treatment of moderate-to-severe atopic dermatitis in white patients.34:Tbaa,Luigi Gargiulo has been a consultant and/or speaker and has participated to advisory boards for Abbvie, Amgen, Almirall, Novartis, Johnson and Johnson, Eli Lilly, Sanofi, Pierre Fabre, BMS, Leo Pharma, UCB, and Pfizer; Caterina Foti has conflict of interest with AbbVie, Almirall, Amgen, Eli Lilly, Incyte, Leo Pharma, Novartis, and Sanofi; Mariateresa Rossi has served as advisory board member and received honoraria for lectures from Almirall, AbbVie, Sanofi, LEO Pharma, Pfizer, Eli Lilly, L’Oréal, Galderma; Serena Giacalone has received honoraria from AbbVie, Johnson and Johnson, Almirall, Sanofi, Leo Pharma, and Novartis. Mariateresa Rossi is an Editorial Board member of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Cataldo Patruno acted as investigator, speaker, consultant, and advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi; Natale Schettini acted as a speaker and consultant for Sanofi, AbbVie, Novartis, Almirall, and Leo Pharma; Niccolò Gori has served as advisory board member and received honoraria for lectures for Almirall, AbbVie, Sanofi, Leo Pharma, Pfizer, Novartis and Galderma; Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galderma, Eli Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung bioepis and Sanofi; Francesca Barei has conflict of interest with Leo Pharma; Katharina Hansel acted as advisor for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Leo Pharma, Novartis, and Sanofi, UCB; Luca Stingeni acted as advisor, speaker and/or investigator for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Incyte, L’Oreal, Leo Pharma, Novartis, Pfizer, Sanofi, UCB; Angelo Valerio Marzano has conflict of interest with AbbVie, Boehringer Ingelheim, Bristol Myers, Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi and UCB; Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim; Silvia M. Ferrucci has conflict of interest with Amgen, Sanofi, Novartis, Lilly, Leo Pharma, Abbvie, Novartis, Menarini. All other authors (Gianluca Avallone, Andrea Bombelli, Ilaria Trave, Elisabetta Magnaterra, Flavia Pigliacelli, Piergiorgio Malagoli, Antonio Portarapillo, Laura Bonzano, Elena Pezzolo, Camilla Chello, Giovanna Brunasso, Federica Veronese, Michela Ortoncelli, Ersilia Tolino, Alan Azzolini, Francesco Bellinato, Eugenia Veronica Di Brizzi, Carlotta Gurioli, Maria Esposito, Roberta Giuffrida, Paolo Calzari, Anna Graziella Burroni, Massimo Gola, Maria Mariano, Maria Concetta Fargnoli, Maddalena Napolitano, Teresa Grieco, Ketty Peris, Paola Savoia, Simone Ribero, Anna Balato and Antonio Costanzo) have nothing to declare.35:Tab7,Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials. To evaluate efficacy and safety of LEB combined with low- to mid-potency topical corticosteroids (TCS) in patients with moderate-to-severe AD. The ADhere trial was a 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, phase 3 clinical trial conducted from February 3, 2020, to September 16, 2021. The study was conducted at 54 outpatient sites across Germany, Poland, Canada, and the US and included adolescent (aged ≥12 to <18 years weighing ≥40 kg) and adult patients with moderate-to-severe AD. The treatment allocation ratio was 2:1 (LEB:PBO). Overall, 211 patients were randomized to subcutaneous LEB (loading dose of 500 mg at baseline and week 2, followed by 250 mg every 2 weeks [Q2W] thereafter) or PBO Q2W in combination with TCS for 16 weeks. Efficacy analyses at week 16 included proportions of patients achieving Investigator's Global Assessment score of 0 or 1 (IGA [0,1]) with 2 or more points improvement from baseline, and 75% improvement in the Eczema Area and Severity Index (EASI-75). Key secondary end points included evaluation of itch, itch interference on sleep, and quality of life. Safety assessments included monitoring adverse events (AEs). The mean (SD) age of patients was 37.2 (19.3) years, 103 (48.8%) patients were women, 31 (14.7%) patients were Asian, and 28 (13.3%) patients were Black/African American. At week 16, IGA (0,1) was achieved by 145 (41.2%) patients in the LEB+TCS group vs 66 (22.1%) receiving PBO+TCS (P = .01); corresponding proportions of patients achieving EASI-75 were 69.5% vs 42.2% (P < .001). The LEB+TCS group showed statistically significant improvements in all key secondary end points. Most treatment-emergent adverse events (TEAEs) were nonserious, mild or moderate in severity, and did not lead to study discontinuation. The TEAEs frequently reported in the LEB+TCS group included conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-reported frequencies in the PBO+TCS group. Similar frequencies of patient-reported serious AEs following LEB+TCS (n = 2, 1.4%) and PBO+TCS (n = 1, 1.5%). In this randomized phase 3 clinical trial, LEB+TCS was associated with improved outcomes in adolescents and adults with moderate-to-severe AD compared with TCS alone, and safety was consistent with previously reported AD trials. ClinicalTrials.gov Identifier: NCT04250337.36:Te1e,ImportanceLebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials.ObjectiveTo evaluate efficacy and safety of LEB combined with low- to mid-potency topical corticosteroids (TCS) in patients with moderate-to-severe AD.Design, Setting, and ParticipantsThe ADhere trial was a 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, phase 3 clinical trial conducted from February 3, 2020, to September 16, 2021. The study was conducted at 54 outpatient sites across Germany, Poland, Canada, and the US and included adolescent (aged ≥12 to &lt;18 years weighing ≥40 kg) and adult patients with moderate-to-severe AD. The treatment allocation ratio was 2:1 (LEB:PBO).InterventionsOverall, 211 patients were randomized to subcutaneous LEB (loading dose of 500 mg at baseline and week 2, followed by 250 mg every 2 weeks [Q2W] thereafter) or PBO Q2W in combination with TCS for 16 weeks.Main Outcomes and MeasuresEfficacy analyses at week 16 included proportions of patients achieving Investigator’s Global Assessment score of 0 or 1 (IGA [0,1]) with 2 or more points improvement from baseline, and 75% improvement in the Eczema Area and Severity Index (EASI-75). Key secondary end points included evaluation of itch, itch interference on sleep, and quality of life. Safety assessments included monitoring adverse events (AEs).ResultsThe mean (SD) age of patients was 37.2 (19.3) years, 103 (48.8%) patients were women, 31 (14.7%) patients were Asian, and 28 (13.3%) patients were Black/African American. At week 16, IGA (0,1) was achieved by 145 (41.2%) patients in the LEB+TCS group vs 66 (22.1%) receiving PBO+TCS (P = .01); corresponding proportions of patients achieving EASI-75 were 69.5% vs 42.2% (P &lt; .001). The LEB+TCS group showed statistically significant improvements in all key secondary end points. Most treatment-emergent adverse events (TEAEs) were nonserious, mild or moderate in severity, and did not lead to study discontinuation. The TEAEs frequently reported in the LEB+TCS group included conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-reported frequencies in the PBO+TCS group. Similar frequencies of patient-reported serious AEs following LEB+TCS (n = 2, 1.4%) and PBO+TCS (n = 1, 1.5%).Conclusions and RelevanceIn this randomized phase 3 clinical trial, LEB+TCS was associated with improved outcomes in adolescents and adults with moderate-to-severe AD compared with TCS alone, and safety was consistent with previously reported AD trials.Trial RegistrationClinicalTrials.gov Identifier: NCT0425033725:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"IL-13 Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on IL-13 Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/IL-13%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"IL-13 Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/IL-13%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"IL-13 Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: IL-13 Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.14309/ajg.0000000000004192","pmid":"42669462","title":"Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results From a Phase 3 Randomized Controlled Trial","journal_title":"American Journal of Gastroenterology","journal_issn":"0002-9270","published_at":"2026-08-28T00:00:00.000Z","url":"https://doi.org/10.14309/ajg.0000000000004192","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-05T06:20:18.555Z","updated_at":"2026-09-05T06:20:18.555Z","tags":[{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"condition","value":"Eosinophilic Duodenitis","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"condition","value":"Eosinophilic Gastritis","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"generic","value":"cendakimab","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"modality","value":"IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"sample_size","value":"n=48","value_numeric":48},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"warning","value":"The abstract does not report statistical significance for symptom domain improvements — only 'numerical improvements' are mentioned, which may indicate those endpoints were not met.","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — no approved treatments currently exist for EG/EoD, making a significant histologic reduction meaningful, but the small sample and Japan-only population warrant caution before wide clinical adoption.","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004192","tag_type":"warning","value":"The 'phase 3' label is used, but the very small sample size (n=48) is atypical for a phase 3 trial; this may reflect the rare-disease/regional trial context.","value_numeric":null}],"summaries":{"what_studied":"A phase 3 randomized, double-blind, placebo-controlled trial evaluated cendakimab (an anti-IL-13 monoclonal antibody) versus placebo in 48 Japanese adults and adolescents with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) over 48 weeks.","key_result":"At week 16, cendakimab significantly reduced mean peak gastrointestinal eosinophil counts versus placebo (least squares mean difference −223.2 eosinophils/high-power field; P=0.003); histologic improvements were maintained at week 48, with numerical but not explicitly quantified symptom improvements and a favorable safety profile.","limitations":"Very small sample size (n=48) limits generalizability; the trial was conducted exclusively in a Japanese population, which may restrict broader applicability; symptom domain improvements were described as numerical only, without reported statistical significance.","practice_takeaway":"Cendakimab (anti-IL-13) produced meaningful and durable reductions in GI eosinophil counts in EG/EoD — a condition with no approved treatments — suggesting IL-13 inhibition is a viable therapeutic strategy worth monitoring as regulatory decisions emerge."}},{"doi":"10.1007/s13555-025-01630-9","pmid":"41526778","title":"Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-01-13T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01630-9","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1007/s13555-025-01630-9","days":"7","issn":"2193-8210","rank":"8","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01630-9","title":"Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice.","journal":"Dermatology and therapy","methods":"","results":"Lebrikizumab reduced all clinical indices by week 4, with improvements maintained through week 16. At week 24, the achievement rates for EASI-50 (50% reduction in EASI), EASI-75 (75% reduction in EASI) and EASI-90 (90% reduction in EASI) were 100%, 75% and 75%, respectively, and the SCORAD-50 (50% reduction in SCORAD) response rate was 64.2%. The proportions of patients achieving a ≥ 4-point reduction in the PP-NRS and in the DLQI at week 24 were 55.8% and 91.6%, respectively. No new safety signals were observed.","abstract":"$30","keywords":["Dermatitis","Eczema","Effectiveness","Interleukin-13","Lebrikizumab","Pruritus","Real-world evidence","Safety"],"pubmed_id":"41526778","conclusions":" Lebrikizumab demonstrated favorable real-world effectiveness and safety over 24 weeks in patients with moderate-to-severe AD, supporting its use in routine clinical practice.","publication_date":"2026-01-13T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01630-9","URL":"https://doi.org/10.1007/s13555-025-01630-9","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01630-9.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01630-9","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01630-9.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice"],"author":[{"given":"Nikolaos","family":"Stavropoulos","sequence":"first","affiliation":[]},{"given":"Daniel","family":"Myszkowski","sequence":"additional","affiliation":[]},{"given":"Dennis","family":"Braß","sequence":"additional","affiliation":[]},{"given":"Vasileios","family":"Dervenis","sequence":"additional","affiliation":[]},{"given":"Effimia","family":"Poungoura","sequence":"additional","affiliation":[]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100022606","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100022606","name":"Almirall","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,12]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2026-01-12T18:36:36Z","timestamp":1768242996000,"date-parts":[[2026,1,12]]},"indexed":{"date-time":"2026-01-14T06:04:11Z","timestamp":1768370651608,"date-parts":[[2026,1,14]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01630-9"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"28 October 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"8 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"12 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"},"order":2,"value":"Nikolaos Stavropoulos has received honoraria for participation in advisory boards, in clinical trials, support for conferences and meetings and/or as a speaker from LEO Pharma, Galderma, Almirall, Johnson&Johnson, Pfizer, Abbvie, and Astra Zeneca. Eggert Stockfleth has received lecture fees from Almirall, Leo, Pierre Favre and Philips. Vasileios Dervenis has received honoraria as a speaker for Abbvie, Almirall, Leo Pharma and support for conferences and meetings by Almirall, Pfizer, Johnson&Johnson, Galderma. Dennis Braß and Effimia Poungoura have received support for conferences and meetings by Pfizer, Johnson&Johnson, Almirall and Galderma. Daniel Myszkowski declares no conflict of interest."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"},"order":3,"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki [\n \n ] and approved by the Westfalen-Lippe Ethics Committee (reference 2025–563-f-S). Because of the retrospective nature of the study, the requirement for informed consent was waived."}],"deposited":{"date-time":"2026-01-13T22:11:28Z","timestamp":1768342288000,"date-parts":[[2026,1,13]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2026,1,12]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1038/s41572-018-0001-z","key":"1630_CR1","year":"2018","issue":"1","author":"S Weidinger","volume":"4","first-page":null,"unstructured":"Weidinger S, Bieber BL, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z.","article-title":null,"journal-title":"Nat Rev Dis Primers","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40265-024-02095-4","key":"1630_CR2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Alvarenga JM, B.T., Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84(11):1379–1394. https://doi.org/10.1007/s40265-024-02095-4.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.12.018","key":"1630_CR3","year":"2019","issue":"7","author":"LC Tsoi","volume":"139","first-page":"1480","unstructured":"Tsoi LC, Degenhardt RE, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480–9. https://doi.org/10.1016/j.jid.2018.12.018.","article-title":null,"journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1630_CR4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"18385500., B.T.A.d.N.E.J.M.A.-d.N.P.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-023-00947-7","key":"1630_CR5","year":"2023","issue":"7","author":"AJ Okragly","volume":"13","first-page":"1535","unstructured":"Okragly AJ, Wulur RA, Wulur I, Daniels M, Van Horn RD, Patel CN, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535–47. https://doi.org/10.1007/s13555-023-00947-7.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad022","key":"1630_CR6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Blauvelt A, T.J., Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–748. https://doi.org/10.1093/bjd/ljad022.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-023-00793-5","key":"1630_CR7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bernardo D, B.T., Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023;24(5):753–764. https://doi.org/10.1007/s40257-023-00793-5.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01550-8","key":"1630_CR8","year":"2025","issue":"12","author":"G Avallone","volume":"15","first-page":"3671","unstructured":"Avallone G, Gargiulo BA, Gargiulo L, Foti C, Trave I, Rossi M, et al. Effectiveness, safety, and health-related quality of life in moderate-to-severe atopic dermatitis treated with lebrikizumab: a 16-week nationwide retrospective cohort study. Dermatol Ther (Heidelb). 2025;15(12):3671–88. https://doi.org/10.1007/s13555-025-01550-8.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":null,"key":"1630_CR9","year":"2023","issue":"2","author":"E Guttman-Yassky","volume":"34","first-page":"203","unstructured":"Guttman-Yassky E, et al. Safety of lebrikizumab in atopic dermatitis: results from clinical trials and real-world experience. J Dermatol Treat. 2023;34(2):203–10.","article-title":null,"journal-title":"J Dermatol Treat","doi-asserted-by":null},{"DOI":"10.1177/17103568251361920","key":"1630_CR10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hagino T, U.A., Kosaka K, Araki T, Saeki H, Fujimoto E, Motegi SI, Kanda N. Thirty-six-week real-world effectiveness of lebrikizumab for different anatomical sites and clinical signs in atopic dermatitis: results from a prospective Japanese study. Dermatitis. 2025. https://doi.org/10.1177/17103568251361920.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"1630_CR11","year":"2022","issue":"1","author":"JI Silverberg","volume":"14","first-page":"34","unstructured":"Silverberg JI, et al. Real-world effectiveness of lebrikizumab compared to other biologics in atopic dermatitis patients. Dermatology Reports. 2022;14(1):34–42.","article-title":null,"journal-title":"Dermatology Reports","doi-asserted-by":null},{"DOI":"10.1001/jama.2013.281053","key":"1630_CR12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"https://doi.org/10.1001/jama.2013.281053.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1610020","key":"1630_CR13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Simpson EL, B.T., Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14888","key":"1630_CR14","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Wollenberg A, B.S., Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. https://doi.org/10.1111/jdv.14888.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17111","key":"1630_CR15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Fauny M, M.K., Domergue Than Trong E, et al. Head and neck dermatitis secondary to Malassezia hypersensitivity in patients treated with dupilumab for atopic dermatitis: a case series. J Eur Acad Dermatol Venereol. 2021;35(5):e338–e341. https://doi.org/10.1111/jdv.17111.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2206714","key":"1630_CR16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Silverberg JI, G.-Y.E., Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Two phase 3 Trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. https://doi.org/10.1056/NEJMoa2206714.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2024.1429709","key":"1630_CR17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lin J, L.M., Zhuo Q, Chen N, Zhang H, Han Y. Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1429709. https://doi.org/10.3389/fphar.2024.1429709.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1630"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"reference-count":17,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,12]]},"references-count":17,"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s13555-025-01630-9","is_oa":true,"title":"Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice","updated":"2026-01-15T02:17:35+00:00","published_date":"2026-01-12","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01630-9.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01630-9.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01630-9"}}},"created_at":"2026-01-20T15:55:50.695Z","updated_at":"2026-01-20T15:55:50.695Z","tags":[{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"generic","value":"lebrikizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"modality","value":"IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"sample_size","value":"n=35","value_numeric":35},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"warning","value":"Five early discontinuations were excluded from analysis, which may inflate response rates.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01630-9","tag_type":"warning","value":"Sample sizes differed by endpoint and timepoint, and denominators were not always explicit.","value_numeric":null}],"summaries":{"what_studied":"Retrospective, single-center real-world study of 35 adults with moderate-to-severe atopic dermatitis treated with lebrikizumab in Germany (Dec 2023–Apr 2025), assessing EASI, SCORAD, PP‑NRS, and DLQI at weeks 4, 16, and 24.","key_result":"By week 24, EASI‑50/EASI‑75/EASI‑90 responses were 100%/75%/75%, SCORAD‑50 was 64.2%, ≥4‑point PP‑NRS reduction was 55.8%, and ≥4‑point DLQI reduction was 91.6%; no new safety signals were observed. Two patients (5.7%) discontinued due to progressive hypereosinophilia; conjunctivitis worsened in 3 (8.6%) with prior history and occurred de novo in 1 (2.9%).","limitations":"Small, retrospective, single-center cohort without a control or active comparator; denominators varied by timepoint and endpoint. Five patients who discontinued before 24 weeks were excluded, which may overestimate response; documentation of concomitant topical therapy was inconsistent.","practice_takeaway":"In adults with moderate-to-severe atopic dermatitis, lebrikizumab produced rapid improvements by week 4 that were sustained through 24 weeks, with high EASI responses and marked QoL gains. Consider monitoring eosinophil counts and respiratory symptoms in patients with prior eosinophilic issues; ocular events were uncommon."}},{"doi":"10.1111/1346-8138.70138","pmid":"41489176","title":"Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study","journal_title":"The Journal of Dermatology","journal_issn":"0385-2407","published_at":"2026-01-05T00:00:00.000Z","url":"https://doi.org/10.1111/1346-8138.70138","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-07","doi":"10.1111/1346-8138.70138","days":"14","issn":"0385-2407","rank":"9","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/1346-8138.70138","title":"Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study.","journal":"The Journal of dermatology","methods":"","results":"","abstract":"$31","keywords":["atopic dermatitis","interleukin‐13","real‐world","site‐specific","tralokinumab"],"pubmed_id":"41489176","conclusions":"","publication_date":"2026-01-05T00:00:00"},"crossref":{"DOI":"10.1111/1346-8138.70138","URL":"https://doi.org/10.1111/1346-8138.70138","ISSN":["0385-2407","1346-8138"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.70138","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.70138","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.70138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study"],"author":[{"given":"Mizuki","family":"Shiba","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital Inzai Japan"}]},{"given":"Teppei","family":"Hagino","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital Inzai Japan"}]},{"given":"Akihiko","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology Gunma University Graduate School of Medicine Maebashi Japan"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School Tokyo Japan"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fujimoto Dermatology Clinic Funabashi Japan"}]},{"given":"Sei‐ichiro","family":"Motegi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Gunma University Graduate School of Medicine Maebashi Japan"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital Inzai Japan"}]}],"funder":[{"id":[{"id":"10.13039/100020377","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100020377","name":"Maruho Takagi Dermatology Foundation","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100016730","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100016730","name":"Torii Pharmaceutical","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,5]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-01-05T11:53:54Z","timestamp":1767614034000,"date-parts":[[2026,1,5]]},"indexed":{"date-time":"2026-01-17T15:17:11Z","timestamp":1768663031505,"date-parts":[[2026,1,17]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000,"date-parts":[[2026,1,5]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000,"date-parts":[[2026,1,5]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.70138"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-11-22"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-25"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-05"}],"deposited":{"date-time":"2026-01-17T04:56:12Z","timestamp":1768625772000,"date-parts":[[2026,1,17]]},"issn-type":[{"type":"print","value":"0385-2407"},{"type":"electronic","value":"1346-8138"}],"published":{"date-parts":[[2026,1,5]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/j.jaci.2006.12.646","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2020.02.008","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.16549","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.mcna.2019.08.009","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/s0140‐6736(20)31286‐1","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2023.100195","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.alit.2021.10.004","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/all.13954","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000499431","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13160","key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/1744666x.2020.1858802","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.12.018","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v101.369","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jmb.2016.12.005","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7573/dic.2021‐1‐7","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2217/imt‐2022‐0307","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15811","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19574","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19573","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.0627","key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257‐022‐00702‐2","key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20832","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/ced/llad038","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2023.0030","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2024.0084","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2023.0261","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2024.4750","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2024.0323","key":"e_1_2_11_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19382","key":"e_1_2_11_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2025.09.034","key":"e_1_2_11_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2024.0538","key":"e_1_2_11_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.17544","key":"e_1_2_11_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5021/ad.24.127","key":"e_1_2_11_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2025.0146","key":"e_1_2_11_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2018.05.029","key":"e_1_2_11_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/all.16108","key":"e_1_2_11_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2024.0515","key":"e_1_2_11_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17103568251367787","key":"e_1_2_11_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17103568251361929","key":"e_1_2_11_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2024.0460","key":"e_1_2_11_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17103568251388043","key":"e_1_2_11_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17103568251380867","key":"e_1_2_11_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.16950","key":"e_1_2_11_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346‐8138.16763","key":"e_1_2_11_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17103568251361920","key":"e_1_2_11_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/1346-8138.70138"],"article-number":"1346-8138.70138","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Journal of Dermatology"],"reference-count":45,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,5]]},"references-count":45,"short-container-title":["The Journal of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/1346-8138.70138","is_oa":true,"title":"Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study","updated":"2026-01-18T01:04:10+00:00","published_date":"2026-01-05","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.70138","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.70138","url_for_landing_page":"https://doi.org/10.1111/1346-8138.70138"}}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1111/1346-8138.70138","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"generic","value":"tralokinumab","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"modality","value":"IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"sample_size","value":"n=208","value_numeric":208},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"warning","value":"Age and sex were not reported in the abstract, limiting assessment of generalizability.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.70138","tag_type":"warning","value":"Prospective vs retrospective design is not stated; classified as a cohort study based on available details.","value_numeric":null}],"summaries":{"what_studied":"A 72-week real-world evaluation of tralokinumab in 208 patients with moderate-to-severe atopic dermatitis, assessing EASI reductions and EASI-75/100 at head/neck, trunk, upper limbs, and lower limbs.","key_result":"By Week 72, site-level EASI-75 was achieved in 80.4% (head/neck), 80.0% (trunk), 80.3% (upper limbs), and 86.7% (lower limbs); EASI-100 in 37.3%, 25.0%, 27.4%, and 40.0%, respectively, with reductions observed across all sites.","limitations":"Single-arm real-world cohort without a comparator; results phrased as “appeared” suggest limited statistical testing; design details and patient demographics are not reported in the abstract.","practice_takeaway":"In routine care, tralokinumab reduced eczema severity over 72 weeks across body sites, with lower limbs showing the highest EASI-75/100 rates and head/neck slightly less responsive. Use these site-level rates to set patient expectations for long-term outcomes."}},{"doi":"10.1007/s13555-025-01550-8","pmid":"41071522","title":"Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2025-10-10T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01550-8","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-13","doi":"10.1007/s13555-025-01550-8","days":"7","issn":"2193-8210","rank":"9","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01550-8","title":"Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.","journal":"Dermatology and therapy","methods":"","results":"At week 16, benefits in disease severity were observed for EASI (- 15.8 ± 9.4, p < 0.0001) and EASI head and neck (- 2.0 ± 1.7, p < 0.0001). QoL significantly improved in 70% of patients (DLQI reduction of - 12.6 ± 9.3, p < 0.0001), accompanied by decreased pruritus (Itch-NRS reduction of - 4.6 ± 3.2, p < 0.0001) and better sleep quality (sleep-NRS reduction of - 4.1 ± 3.4, p < 0.0001). A 76% reduction in BSA score was recorded, 85% of subjects improved their IGA index, with 62% achieving a score of 0-1, and SCORAD and POEM assessments significantly improved (p < 0.0001). Patients perceived a better control of the disease (ADCT, - 10.9 ± 7.1, p < 0.0001), and 14% of patients achieved MDA. Anxiety and depression levels decreased. Four mild adverse events were registered.","abstract":"$33","keywords":["Atopic dermatitis","Biologics","IL-13 inhibitor","Lebrikizumab","Monoclonal antibodies","Multi-failure","Skin disease"],"pubmed_id":"41071522","conclusions":"","publication_date":"2025-10-10T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01550-8","URL":"https://doi.org/10.1007/s13555-025-01550-8","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01550-8.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01550-8/fulltext.html","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01550-8.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study"],"author":[{"given":"Gianluca","family":"Avallone","sequence":"first","affiliation":[]},{"given":"Andrea","family":"Bombelli","sequence":"additional","affiliation":[]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[]},{"given":"Ilaria","family":"Trave","sequence":"additional","affiliation":[]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[]},{"given":"Elisabetta","family":"Magnaterra","sequence":"additional","affiliation":[]},{"given":"Flavia","family":"Pigliacelli","sequence":"additional","affiliation":[]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[]},{"given":"Serena","family":"Giacalone","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Portarapillo","sequence":"additional","affiliation":[]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[]},{"given":"Natale","family":"Schettini","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Bonzano","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[]},{"given":"Camilla","family":"Chello","sequence":"additional","affiliation":[]},{"given":"Niccolò","family":"Gori","sequence":"additional","affiliation":[]},{"given":"Giovanna","family":"Brunasso","sequence":"additional","affiliation":[]},{"given":"Federica","family":"Veronese","sequence":"additional","affiliation":[]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[]},{"given":"Alan","family":"Azzolini","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[]},{"given":"Carlotta","family":"Gurioli","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[]},{"given":"Roberta","family":"Giuffrida","sequence":"additional","affiliation":[]},{"given":"Francesca","family":"Barei","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Calzari","sequence":"additional","affiliation":[]},{"given":"Anna Graziella","family":"Burroni","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Gola","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Mariano","sequence":"additional","affiliation":[]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Grieco","sequence":"additional","affiliation":[]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,10,10]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2025-10-10T06:52:41Z","timestamp":1760079161000,"date-parts":[[2025,10,10]]},"indexed":{"date-time":"2025-10-10T08:42:28Z","timestamp":1760085748794,"date-parts":[[2025,10,10]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000,"date-parts":[[2025,10,10]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000,"date-parts":[[2025,10,10]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01550-8"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"12 August 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"15 September 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"10 October 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"$34"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"},"order":3,"value":"The study adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines for cohort studies and the principles outlined in the Declaration of Helsinki. Ethical approval was granted by an institutional review board (Ethics Approval Committee Lombardia 3, protocol number Lebri-AD-2024). All patients provided written informed consent to participate in the study and for publication."}],"deposited":{"date-time":"2025-10-10T08:03:46Z","timestamp":1760083426000,"date-parts":[[2025,10,10]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2025,10,10]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1093/bjd/ljad339","key":"1550_CR1","year":"2023","issue":null,"author":"J Tian","volume":"190","first-page":"55","unstructured":"Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55–61.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)02519-4","key":"1550_CR2","year":"2025","issue":null,"author":"E Guttman-Yassky","volume":"405","first-page":"583","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583–96.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.13401","key":"1550_CR3","year":"2018","issue":null,"author":"S Barbarot","volume":"73","first-page":"1284","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284–93.","article-title":null,"journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2023.1165098","key":"1550_CR4","year":"2023","issue":null,"author":"M Napolitano","volume":"10","first-page":"1165098","unstructured":"Napolitano M, Di Vico F, Ruggiero A, Fabbrocini G, Patruno C. The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1165098.","article-title":null,"journal-title":"Front Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2012.07.012","key":"1550_CR5","year":"2012","issue":null,"author":"JK Gittler","volume":"130","first-page":"1344","unstructured":"Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–54.","article-title":null,"journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMra2023911","key":"1550_CR6","year":"2021","issue":null,"author":"S Ständer","volume":"384","first-page":"1136","unstructured":"Ständer S. Atopic dermatitis. N Engl J Med. 2021;384:1136–43.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms24010837","key":"1550_CR7","year":"2023","issue":null,"author":"A Mesjasz","volume":"24","first-page":"837","unstructured":"Mesjasz A, Zawadzka M, Chałubiński M, Trzeciak M. Is atopic dermatitis only a skin disease? IJMS. 2023;24:837.","article-title":null,"journal-title":"IJMS","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-023-00793-5","key":"1550_CR8","year":"2023","issue":null,"author":"D Bernardo","volume":"24","first-page":"753","unstructured":"Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023;24:753–64.","article-title":null,"journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.18176/jiaci.0906","key":"1550_CR9","year":"2023","issue":null,"author":"J Armario-Hita","volume":"33","first-page":"158","unstructured":"Armario-Hita J, Galán-Gutiérrez M, Dodero-Anillo J, Carrascosa J, Ruiz-Villaverde R. Updated review on treatment of atopic dermatitis. J Investig Allergol Clin. 2023;33:158–67.","article-title":null,"journal-title":"J Investig Allergol Clin","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20639","key":"1550_CR10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: living update. Acad Dermatol Venereol. 2025;39(9):1537–66. https://doi.org/10.1111/jdv.20639.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.23736/S2784-8671.24.07664-3","key":"1550_CR11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Argenziano G, Cusano F, Corazza M, et al. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Ital J Dermatol Venereol. 2024;159:223–50. https://www.minervamedica.it/index2.php?show=R23Y2024N03A0223. Accessed 2025 May 15.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-025-01357-7","key":"1550_CR12","year":"2025","issue":null,"author":"JI Silverberg","volume":"15","first-page":"615","unstructured":"Silverberg JI, Bieber T, Paller AS, et al. Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy. Dermatol Ther (Heidelb). 2025;15:615–33.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1080/14712598.2024.2435427","key":"1550_CR13","year":"2025","issue":null,"author":"L Stingeni","volume":"25","first-page":"15","unstructured":"Stingeni L, Ferrucci S, Amerio P, Foti C, Patruno C, Girolomoni G. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. Expert Opin Biol Ther. 2025;25:15–20.","article-title":null,"journal-title":"Expert Opin Biol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae394","key":"1550_CR14","year":"2025","issue":null,"author":"N Katoh","volume":"192","first-page":"597","unstructured":"Katoh N, Tanaka A, Takahashi H, et al. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J). Br J Dermatol. 2025;192:597–610.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2024.2442720","key":"1550_CR15","year":"2025","issue":null,"author":"A Blauvelt","volume":"36","first-page":"2442720","unstructured":"Blauvelt A, Kircik L, Schlesinger T, et al. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025;36:2442720.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-024-01158-4","key":"1550_CR16","year":"2024","issue":null,"author":"EL Simpson","volume":"14","first-page":"1145","unstructured":"Simpson EL, De Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:1145–60.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2025.0045","key":"1550_CR17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hagino T, Uchiyama A, Onda M, et al. 24-Week real-world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: an analysis stratified by prior systemic therapy. Dermatitis. 2025. https://doi.org/10.1089/derm.2025.0045.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2025.000","key":"1550_CR18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: a 16-week study in Japan. Dermatitis. 2025. https://doi.org/10.1089/derm.2025.000.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2025.0046","key":"1550_CR19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world Japanese study of the effectiveness and safety of switching from dupilumab to lebrikizumab in patients with moderate to severe atopic dermatitis. Dermatitis. 2025. https://doi.org/10.1089/derm.2025.0046.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20660","key":"1550_CR20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hagino T, Uchiyama A, Kosaka K, et al. Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis. Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.20660.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm12072701","key":"1550_CR21","year":"2023","issue":null,"author":"A Chiricozzi","volume":"12","first-page":"2701","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. JCM. 2023;12:2701.","article-title":null,"journal-title":"JCM","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(07)61602-X","key":"1550_CR22","year":"2007","issue":null,"author":"E von Elm","volume":"370","first-page":"1453","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.18176/jiaci.0138","key":"1550_CR23","year":"2017","issue":null,"author":"J Silvestre Salvador","volume":"27","first-page":"78","unstructured":"Silvestre Salvador J, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27:78–88.","article-title":null,"journal-title":"J Investig Allergol Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1034/j.1600-0625.2001.100102.x","key":"1550_CR24","year":"2001","issue":null,"author":"JM Hanifin","volume":"10","first-page":"11","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11–8.","article-title":null,"journal-title":"Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"1550_CR25","year":"1994","issue":null,"author":"AY Finlay","volume":"19","first-page":"210","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.","article-title":null,"journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17744","key":"1550_CR26","year":"2019","issue":null,"author":"G Yosipovitch","volume":"181","first-page":"761","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761–9.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12955-021-01877-8","key":"1550_CR27","year":"2021","issue":null,"author":"JI Silverberg","volume":"19","first-page":"247","unstructured":"Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19:247.","article-title":null,"journal-title":"Health Qual Life Outcomes","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-023-02528-8","key":"1550_CR28","year":"2023","issue":null,"author":"JP Thyssen","volume":"40","first-page":"3574","unstructured":"Thyssen JP, De Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40:3574–87.","article-title":null,"journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.104","key":"1550_CR29","year":"2020","issue":null,"author":"E Simpson","volume":"83","first-page":"839","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83:839–46.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000247298","key":"1550_CR30","year":"1993","issue":null,"author":"JF Stalder","volume":"186","first-page":"23","unstructured":"Stalder JF, Taïeb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.","article-title":null,"journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.140.12.1513","key":"1550_CR31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140:1513–9. https://doi.org/10.1001/archderm.140.12.1513.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/03007995.2019.1699516","key":"1550_CR32","year":"2020","issue":null,"author":"DM Pariser","volume":"36","first-page":"367","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36:367–76.","article-title":null,"journal-title":"Curr Med Res Opin","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac140.022","key":"1550_CR33","year":"2023","issue":null,"author":"JI Silverberg","volume":"188","first-page":"ljac140.022","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. 327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. British Journal of Dermatology. 2023;188:ljac140.022.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1600-0447.1983.tb09716.x","key":"1550_CR34","year":"1983","issue":null,"author":"AS Zigmond","volume":"67","first-page":"361","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70.","article-title":null,"journal-title":"Acta Psychiatr Scand","doi-asserted-by":"publisher"},{"DOI":"10.23736/S2784-8671.25.08001-6","key":"1550_CR35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Blicharz L, Michalczyk A, Maj M, Czuwara J, Olszewska M, Rudnicka L. Head and neck dermatitis: a variant of atopic dermatitis. Ital J Dermatol Venereol. 2025;160:123–144. https://doi.org/10.23736/S2784-8671.25.08001-6.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2206714","key":"1550_CR36","year":"2023","issue":null,"author":"JI Silverberg","volume":"388","first-page":"1080","unstructured":"Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080–91.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad022","key":"1550_CR37","year":"2023","issue":null,"author":"A Blauvelt","volume":"188","first-page":"740","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188:740–8.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.5534","key":"1550_CR38","year":"2023","issue":null,"author":"EL Simpson","volume":"159","first-page":"182","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159:182.","article-title":null,"journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.01.017","key":"1550_CR39","year":"2018","issue":null,"author":"EL Simpson","volume":"78","first-page":"863","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863-871.e11.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.0079","key":"1550_CR40","year":"2020","issue":null,"author":"E Guttman-Yassky","volume":"156","first-page":"411","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156:411.","article-title":null,"journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-024-01226-9","key":"1550_CR41","year":"2024","issue":null,"author":"JI Silverberg","volume":"14","first-page":"2249","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment. Dermatol Ther (Heidelb). 2024;14:2249–60.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2024.1429709","key":"1550_CR42","year":"2024","issue":null,"author":"J Lin","volume":"15","first-page":"1429709","unstructured":"Lin J, Luo M, Zhuo Q, Chen N, Zhang H, Han Y. Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1429709.","article-title":null,"journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.alit.2024.08.010","key":"1550_CR43","year":"2025","issue":null,"author":"M Kido-Nakahara","volume":"74","first-page":"222","unstructured":"Kido-Nakahara M, Chiba T, Mizusawa Y, et al. Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk. Allergol Int. 2025;74:222–32.","article-title":null,"journal-title":"Allergol Int","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-024-46540-0","key":"1550_CR44","year":"2024","issue":null,"author":"C Bangert","volume":"15","first-page":"2839","unstructured":"Bangert C, Alkon N, Chennareddy S, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15:2839.","article-title":null,"journal-title":"Nat Commun","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.11.047","key":"1550_CR45","year":"2023","issue":null,"author":"LA Beck","volume":"88","first-page":"816","unstructured":"Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2023;88:816–23.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cells13161398","key":"1550_CR46","year":"2024","issue":null,"author":"J Laska","volume":"13","first-page":"1398","unstructured":"Laska J, Tota M, Łacwik J, Sędek Ł, Gomułka K. IL-22 in atopic dermatitis. Cells. 2024;13:1398.","article-title":null,"journal-title":"Cells","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2025.01.013","key":"1550_CR47","year":"2025","issue":null,"author":"S Meledathu","volume":"155","first-page":"1124","unstructured":"Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol. 2025;155:1124–32.","article-title":null,"journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19929","key":"1550_CR48","year":"2024","issue":null,"author":"N Gori","volume":"38","first-page":"e852","unstructured":"Gori N, Ippoliti E, Ferrucci SM, et al. Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series. J Eur Acad Dermatol Venereol. 2024;38:e852–4.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.16926","key":"1550_CR49","year":"2024","issue":null,"author":"MA Lasheras-Pérez","volume":"63","first-page":"105","unstructured":"Lasheras-Pérez MA, Palacios-Diaz RD, Pozuelo-Ruiz M, Torres-Navarro I, Botella-Estrada R, Rodriguez-Serna M. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol. 2024;63:105–7.","article-title":null,"journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-023-01058-z","key":"1550_CR50","year":"2024","issue":null,"author":"K Rand","volume":"14","first-page":"169","unstructured":"Rand K, Ramos-Goñi JM, Akmaz B, Solé-Feu L, Armario-Hita J-C. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:169–82.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1550"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"reference-count":50,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,10]]},"references-count":50,"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s13555-025-01550-8","is_oa":true,"title":"Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study","updated":"2025-10-12T00:01:44+00:00","published_date":"2025-10-10","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01550-8.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01550-8.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01550-8"}}},"created_at":"2025-10-19T07:07:31.491Z","updated_at":"2025-10-19T07:07:31.491Z","tags":[{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"generic","value":"lebrikizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"modality","value":"IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"sample_size","value":"n=78","value_numeric":78},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"warning","value":"Adverse event counts differ between sections (abstract lists four mild AEs; plain-language summary mentions three mild side effects plus one relapse).","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"warning","value":"Observational, uncontrolled design with only 16 weeks of follow-up; results are associative, not causal.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01550-8","tag_type":"warning","value":"Some secondary outcomes (e.g., HADS, DLQI) had small numbers and missing data, limiting precision.","value_numeric":null}],"summaries":{"what_studied":"A 16-week retrospective multicenter cohort of 78 adults with moderate-to-severe atopic dermatitis received lebrikizumab; disease severity (primary: EASI) and multiple patient- and clinician-reported secondary outcomes were assessed, including safety. Patients were both biologic/JAK inhibitor–naïve and –experienced; there was no control group.","key_result":"At week 16, mean EASI decreased by 15.8±9.4 points (−75.4%), with EASI75/90/100 achieved by 48/78 (61.5%), 22/78 (28.2%), and 7/78 (9.0%). DLQI improved in 70% (mean −12.6±9.3), itch NRS fell by 4.6±3.2, and four mild adverse events occurred (3 conjunctivitis, 1 facial redness) with no discontinuations.","limitations":"Retrospective, uncontrolled design with a short 16-week follow-up limits causal inference. Several PROs had small, incomplete samples and subgroup comparisons were exploratory with baseline imbalances; prior and concomitant therapies may confound results. The predominantly white cohort limits generalizability to other ethnic groups.","practice_takeaway":"In routine practice, lebrikizumab produced large 16‑week improvements in AD severity, itch, sleep, and QoL in adults—including those previously treated with biologics/JAK inhibitors—with few mild AEs; monitor for conjunctivitis. Use these data as supportive real‑world evidence, but interpret alongside the short, uncontrolled follow‑up."}},{"doi":"10.1001/jamadermatol.2022.5534","pmid":"36630140","title":"Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2023-01-12T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2022.5534","source_score":37,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-02-03","doi":"10.1001/jamadermatol.2022.5534","days":"30","issn":"2168-6068","rank":"4","field":"Clinical Medicine","score":"37","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2022.5534","title":"Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).","journal":"JAMA dermatology","methods":"","results":"The mean (SD) age of patients was 37.2 (19.3) years, 103 (48.8%) patients were women, 31 (14.7%) patients were Asian, and 28 (13.3%) patients were Black/African American. At week 16, IGA (0,1) was achieved by 145 (41.2%) patients in the LEB+TCS group vs 66 (22.1%) receiving PBO+TCS (P = .01); corresponding proportions of patients achieving EASI-75 were 69.5% vs 42.2% (P < .001). The LEB+TCS group showed statistically significant improvements in all key secondary end points. Most treatment-emergent adverse events (TEAEs) were nonserious, mild or moderate in severity, and did not lead to study discontinuation. The TEAEs frequently reported in the LEB+TCS group included conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-reported frequencies in the PBO+TCS group. Similar frequencies of patient-reported serious AEs following LEB+TCS (n = 2, 1.4%) and PBO+TCS (n = 1, 1.5%).","abstract":"$35","keywords":[],"pubmed_id":"36630140","conclusions":"","publication_date":"2023-01-12T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2022.5534","URL":"https://doi.org/10.1001/jamadermatol.2022.5534","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2800236/jamadermatology_simpson_2023_oi_220065_1689626986.18217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"182","type":"journal-article","issue":"2","score":1,"title":["Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis"],"author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Skin for Dermatology, Peterborough, Ontario, Canada"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"LMU - Department of Dermatology and Allergology, Munich, Germany"},{"name":"Department of Dermatology, Free University Brussels, University Hospital Brussels, Brussels, Belgium"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Christian Albrechts University of Kiel, Kiel, Germany"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of the USC, Los Angeles, California"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"Southern California Dermatology, Inc, Santa Ana"}]},{"given":"Silvia","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dermatology Unit, Milan, Italy"}]},{"given":"Renata Gontijo","family":"Lima","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Michael M.","family":"Witte","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Hany","family":"ElMaraghy","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Chitra R.","family":"Natalie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center, Portland"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Abel","family":"Jarell","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Neil","family":"Sadick","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Paul W","family":"Wallace","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jose M","family":"Carpio","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"David","family":"Greenstein","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jose M","family":"Mendez","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Scott T","family":"Guenthner","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Wendy L","family":"McFalda","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Vivian T","family":"Laquer","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jeffrey J","family":"Crowley","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Ricardo","family":"Tan","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Francis J","family":"Averill","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Rosalyn E","family":"George","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Eddie","family":"Armas","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Walter K","family":"Nahm","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Alison A","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Sunil S","family":"Dhawan","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Eric L","family":"Simpson","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Steve","family":"Sitar","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Bruce","family":"Torkan","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"David F","family":"Fivenson","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jamie D","family":"Weisman","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Melody L","family":"Stone","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Mirwais","family":"Saifi","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Brad P","family":"Glick","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Isaiah","family":"Day","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Lorne","family":"Albrecht","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Marni","family":"Wiseman","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"David","family":"Gratton","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Chi-Ho","family":"Hong","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Bernadetta","family":"Majorek-Olechowska","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Beata","family":"Krecisz","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Irena","family":"Walecka-Herniczek","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Jolanta","family":"Weglowska","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Beata","family":"Bergler-Czop","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Boguslawa","family":"Cimoszko","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Kamila","family":"Padlewska","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Maria","family":"Czubek","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Thomas","family":"Wildfeuer","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]},{"given":"Roland","family":"Aschoff","sequence":"additional","affiliation":[{"name":"for the ADhere Investigators"}]}],"issued":{"date-parts":[[2023,2,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"159","created":{"date-time":"2023-01-11T11:05:09Z","timestamp":1673435109000,"date-parts":[[2023,1,11]]},"indexed":{"date-time":"2025-09-20T21:26:56Z","timestamp":1758403616835,"date-parts":[[2025,9,20]]},"subject":[],"abstract":"$36","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2800236"}},"subtitle":["A Randomized Clinical Trial (ADhere)"],"deposited":{"date-time":"2023-07-19T11:22:53Z","timestamp":1689765773000,"date-parts":[[2023,7,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2023,2,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S0140-6736(20)31286-1","key":"doi220065r1","year":"2020","issue":"10247","author":"Langan","volume":"396","first-page":"345","unstructured":null,"article-title":"Atopic dermatitis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/cea.2007.37.issue-4","key":"doi220065r2","year":"2007","issue":"4","author":"Harrop","volume":"37","first-page":"526","unstructured":null,"article-title":"Eczema, atopy and allergen exposure in adults: a population-based study.","journal-title":"Clin Exp Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14167","key":"doi220065r3","year":"2016","issue":"2","author":"Diepgen","volume":"174","first-page":"319","unstructured":null,"article-title":"Prevalence of contact allergy in the general population in different European regions.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clindermatol.2018.05.007","key":"doi220065r4","year":"2018","issue":"5","author":"Sacotte","volume":"36","first-page":"595","unstructured":null,"article-title":"Epidemiology of adult atopic dermatitis.","journal-title":"Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jde.2006.33.issue-11","key":"doi220065r5","year":"2006","issue":"11","author":"Saeki","volume":"33","first-page":"817","unstructured":null,"article-title":"Prevalence of atopic dermatitis determined by clinical examination in Japanese adults.","journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11882-008-0049-z","key":"doi220065r6","year":"2008","issue":"4","author":"Yosipovitch","volume":"8","first-page":"306","unstructured":null,"article-title":"What causes itch in atopic dermatitis?","journal-title":"Curr Allergy Asthma Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2018.07.006","key":"doi220065r7","year":"2018","issue":"3","author":"Silverberg","volume":"121","first-page":"340","unstructured":null,"article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2017.09.076","key":"doi220065r8","year":"2017","issue":"6","author":"Vakharia","volume":"119","first-page":"548","unstructured":null,"article-title":"Burden of skin pain in atopic dermatitis.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.4081/dr.2012.e1","key":"doi220065r9","year":"2011","issue":"1","author":"Ricci","volume":"4","first-page":null,"unstructured":null,"article-title":"Atopic dermatitis in adolescence.","journal-title":"Dermatol Reports","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.10.010","key":"doi220065r10","year":"2014","issue":"2","author":"Eichenfield","volume":"70","first-page":"338","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.03.030","key":"doi220065r11","year":"2014","issue":"2","author":"Sidbury","volume":"71","first-page":"327","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2019.1582403","key":"doi220065r12","year":"2019","issue":"9","author":"Thibodeaux","volume":"15","first-page":"2129","unstructured":null,"article-title":"A review of dupilumab in the treatment of atopic diseases.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.5414/ALX02259E","key":"doi220065r13","year":"2021","issue":null,"author":"Stölzl","volume":"5","first-page":"265","unstructured":null,"article-title":"A new era has begun: Treatment of atopic dermatitis with biologics.","journal-title":"Allergol Select","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi220065r14","year":"2022","issue":"5","author":"Drucker","volume":"158","first-page":"523","unstructured":null,"article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis.","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.2018.32.issue-5","key":"doi220065r15","year":"2018","issue":"5","author":"Wollenberg","volume":"32","first-page":"657","unstructured":null,"article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.2018.32.issue-6","key":"doi220065r16","year":"2018","issue":"6","author":"Wollenberg","volume":"32","first-page":"850","unstructured":null,"article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.v75.1","key":"doi220065r17","year":"2020","issue":"1","author":"Bieber","volume":"75","first-page":"54","unstructured":null,"article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/exd.2019.28.issue-7","key":"doi220065r18","year":"2019","issue":"7","author":"Moyle","volume":"28","first-page":"756","unstructured":null,"article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.","journal-title":"Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.12.018","key":"doi220065r19","year":"2019","issue":"7","author":"Tsoi","volume":"139","first-page":"1480","unstructured":null,"article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.0079","key":"doi220065r21","year":"2020","issue":"4","author":"Guttman-Yassky","volume":"156","first-page":"411","unstructured":null,"article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2018.10.032","key":"doi220065r24","year":"2019","issue":"1","author":"Czarnowicki","volume":"143","first-page":"1","unstructured":null,"article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2013.281053","key":"doi220065r25","year":"2013","issue":"20","author":"World Medical Association","volume":"310","first-page":"2191","unstructured":null,"article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2015-207841","key":"doi220065r26","year":"2015","issue":"12","author":"Winthrop","volume":"74","first-page":"2107","unstructured":null,"article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3751","key":"doi220065r27","year":"2021","issue":"2","author":"De Bruin-Weller","volume":"101","first-page":null,"unstructured":null,"article-title":"Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.01.017","key":"doi220065r28","year":"2018","issue":"5","author":"Simpson","volume":"78","first-page":"863","unstructured":null,"article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE).","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.v77.8","key":"doi220065r30","year":"2022","issue":"8","author":"Hansen","volume":"77","first-page":"2555","unstructured":null,"article-title":"IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31191-1","key":"doi220065r31","year":"2017","issue":"10086","author":"Blauvelt","volume":"389","first-page":"2287","unstructured":null,"article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.v186.3","key":"doi220065r32","year":"2022","issue":"3","author":"Gutermuth","volume":"186","first-page":"440","unstructured":null,"article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi220065r20","year":"2021","issue":null,"author":"Okragly","volume":null,"first-page":null,"unstructured":null,"article-title":"Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. Paper presented at: Inflammatory Skin Disease Summit.","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi220065r22","year":"2022","issue":null,"author":"Silverberg","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi220065r23","year":"2022","issue":null,"author":"Pillai","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi220065r29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ClinicalTrials.gov. A study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with atopic dermatitis. Accessed May 6, 2022. https://clinicaltrials.gov/ct2/show/NCT02465606?term=NCT02465606&rank=1","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2023,2,1]]},"reference-count":32,"published-online":null,"references-count":32,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":86},"unpaywall":{"doi":"10.1001/jamadermatol.2022.5534","is_oa":true,"title":"Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis","updated":"2025-07-30T00:59:52+00:00","published_date":"2023-01-11","best_oa_location":{"url":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2800236/jamadermatology_simpson_2023_oi_220065_1675100217.46979.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2800236/jamadermatology_simpson_2023_oi_220065_1675100217.46979.pdf","url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2022.5534"}}},"created_at":"2025-09-22T14:20:55.574Z","updated_at":"2025-09-22T14:20:55.574Z","tags":[{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"generic","value":"lebrikizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"modality","value":"IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"sample_size","value":"n=211","value_numeric":211},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"warning","value":"Event counts paired with percentages for IGA/EASI appear internally inconsistent; interpret absolute counts with caution.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2022.5534","tag_type":"warning","value":"Only 16-week outcomes are reported here; longer-term combination data are not included in this summary.","value_numeric":null}],"summaries":{"what_studied":"A 16-week randomized, double-blind, placebo-controlled, multicenter phase 3 trial tested lebrikizumab added to low- to mid-potency topical corticosteroids vs placebo plus topical corticosteroids in adolescents (≥12 years, ≥40 kg) and adults with moderate-to-severe atopic dermatitis.","key_result":"At week 16, IGA 0/1 with ≥2-point improvement was achieved by 145 (41.2%) on lebrikizumab+TCS vs 66 (22.1%) on placebo+TCS (P=.01); EASI-75 was 69.5% vs 42.2% (P<.001). Serious adverse events were similar (1.4% vs 1.5%); conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection-site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) were more frequent with lebrikizumab+TCS than placebo+TCS (≤1.5%).","practice_takeaway":"For adolescents and adults with moderate-to-severe atopic dermatitis, adding lebrikizumab to low- to mid-potency topical steroids for 16 weeks improved skin clearance and itch outcomes over steroids alone, with mostly mild to moderate adverse events and similar rates of serious events. The safety profile was consistent with prior AD trials."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"IL-13 Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"IL-13 Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"IL-13 Inhibitor"}}}]]

Papers